Session Information

Sponsored Seminar

[ILS-WE-02] Lunch Seminar 2: Towards a deeper understanding of wet AMD therapy: optimizing benefits, managing risks and individualizing care
Go back
print
Day
Apr 02 (Wed)
Time
12:15 - 13:15
Room
Room 17 - Imperial Hotel 2F Peacock (East)
Sponsor
Novartis Pharma AG
Topic
Retina, Vitreous body
Chair/Coordinator
Chair)Masahito Ohji
Description
The incidence of blindness due to wet age-related macular degeneration (AMD) has reduced considerably since the introduction of anti-VEGF agents, notably ranibizumab. Building on this success requires a deeper understanding of wet AMD pathology. This in turn can provide insights into how variation between individual patients can lead to differences in their risk of developing the disease as well as their responses to treatment. In order to minimize risk and maximize vision outcomes, the choice of wet AMD therapy should be defined by efficacy, safety and dosing strategy, according to the individual needs of the patient.

ILS-WE-02 / 

Retina, Vitreous body

Ranibizumab in wet AMD: building on success and improving patient outcomes

Masahito Ohji

Ranibizumab in wet AMD: building on success and improving patient outcomes

ILS-WE-02 / 

Retina, Vitreous body

Can genetics provide the answer to optimal wet AMD treatment?

Gregory Hageman

Can genetics provide the answer to optimal wet AMD treatment?

ILS-WE-02 / 

Retina, Vitreous body

The balancing act between efficacy and safety to bring the best benefits to patients

Pravin Dugel

The balancing act between efficacy and safety to bring the best benefits to patients

Go back